Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of October 2018. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing serves to incorporate by reference a press release dated October 3, 2018 (Exhibit 99.1), into the company's active Registration Statements on Forms F-3 and S-8.
Financial Metrics
The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing acts solely as a conduit for the attached press release.
Material Changes
The filing text does not detail specific material changes or comparative financial performance versus prior periods. It references the issuance of a press release but does not summarize the content of that release within the body of the Form 6-K.
Guidance, Outlook, and Risks
No guidance, outlook, management commentary, risks, contingencies, or unusual items are described in the provided text. The document states that the information in the attached press release is incorporated by reference, but the text of the press release itself is not included in the input.
Key Facts for Investor Verification
- Verify the content of the attached Exhibit 99.1 (Press Release dated October 3, 2018) to understand the material event triggering this filing.
- Confirm the registrant name is Galapagos NV, as the metadata reference to "Lakefront Biotherapeutics NV" appears to be incorrect based on the filing text.
- Note that this filing updates Registration Statements File No. 333-211765 (Form F-3) and multiple Form S-8 filings.
- Check the company's Form 20-F annual reports for the actual financial metrics, as this Form 6-K contains none.